The FDA had expressed some concerns regarding Twirla's safety, efficacy, and the company's proposed label. However, the AdCom members voted 14-1 with one abstention in favor of approval. AGRX went from trading at 52-week low, to rocketing up to a 52-week high following the positive AdCom vote. PRINCETON, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of Twirla(R) (levonorgestrel/ethinyl "敏捷疗法公司(纳斯达克股票代码：AGRX)刚刚证明了这句话的智慧。 2017年12月，Agile就其避孕贴片Twirla收到了美国食品药品监督管理局(FDA)的完整回复信(CRL)。FDA拒绝了该生物技术法规的提交，因为它担心用于制造贴剂的质量附着力测试方法。 Alfred F. Altomari: Currently, Alfred F. Altomari holds the position of Chairman & Chief Executive Officer of Agile Therapeutics, Inc. and Chairman of Baudax Bio, Inc. Mr. Altomari is also on the board of Insmed, Inc., NB Therapeutics, Inc. (former Chairman), BioNJ, Inc. and Trenton Area Soup Kitchen and Director-Charles D Close School at Drexel University.
制药公司Agile Therapeutics(AGRX.US)盘初跌超45%，Q3净亏损同 …
盘前个股动态2016 < 个股探索 > - 钱多多 股票论坛 … Aug 08, 2010 医药a股票收益公 _淘股吧 - taoguba.com.cn 淘股吧医药a股票收益公列表栏目，每天为您提供海量丰富的医药a股票收益公文章资讯内容，医药a股票收益公相关话题讨论，医药a股票收益公相关概念股票及医药a股票收益公相关炒股用户信息服务，欢迎广大股民积极参与医药a股票收益公话题讨论。 生物制药：本周开启反弹，下周能否延续？ - 老虎社区
The FDA had expressed some concerns regarding Twirla's safety, efficacy, and the company's proposed label. However, the AdCom members voted 14-1 with one abstention in favor of approval. AGRX went from trading at 52-week low, to rocketing up to a 52-week high following the positive AdCom vote.
Sign in to follow more topics that interest you and track them on all your devices Trending Articles 10 Cheap Stocks to Buy Under $10 4 days ago J.P. Morgan Says These Are the 3 Stocks to Buy May 29, 2020 The 5G Revolution Could Send These 3 Stocks Higher 6 days ago 免責聲明： 在此提供的資料由經濟通有限公司（「經濟通」）及／或其第三方信息提供者（「來源公司」）提供，僅供參考之用，而非旨在提供任何財務或專業意見；因此，任何人不應賴以作為有關此方面的用途。 Euronext strengthens its post-trade business with the acquisition of VP Securities, the Danish Central Securities Depository. Capital Markets Update Performance of our markets and data trends, including relevant information on legal and regulatory measures in Euronext countries ESG Guidelines for listed companies The online brokerage that makes you a smarter investor Our knowledgeable professionals and industry leading tools are united to do one thing: make you a smarter, more confident investor. Open new account Learn more. When the market swings, learn how to swing back. Get expert insights to help navigate the ups and downs of the market with Market Data Disclaimer | © 2020 Seeking Alpha
The FDA had expressed some concerns regarding Twirla's safety, efficacy, and the company's proposed label. However, the AdCom members voted 14-1 with one abstention in favor of approval. AGRX went from trading at 52-week low, to rocketing up to a 52-week high following the positive AdCom vote.
雪球为您提供Agile Therapeutics(AGRX)股票实时行情,资金流向,新闻资讯,研究报告,社区互动,交易信息,个股点评,公告,财务指标分析等与Agile Therapeutics(AGRX)股票相关的信息与服务. 新浪财经-美股频道为您提供agrx(agrx)股票股价,股票实时行情,新闻,财报,美股实时交易数据,研究报告,评级,财务指标分析等与agrx(agrx)股票相关的信息与服务 ”敏捷疗法公司(纳斯达克股票代码：AGRX)刚刚证明了这句话的智慧。 2017年12月，Agile就其避孕贴片Twirla收到了美国食品药品监督管理局(FDA)的完整回复信(CRL)。FDA拒绝了该生物技术法规的提交，因为它担心用于制造贴剂的质量附着力测试方法。 PRINCETON, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of Twirla(R) (levonorgestrel/ethinyl The FDA had expressed some concerns regarding Twirla's safety, efficacy, and the company's proposed label. However, the AdCom members voted 14-1 with one abstention in favor of approval. AGRX went from trading at 52-week low, to rocketing up to a 52-week high following the positive AdCom vote.
我们的投资项目 - 维梧资本|专注医疗健康领域的投资公司
【昨日盘后上涨跌】 盘后下跌股票 财报财测影响:AMAG GG LPI CF A SB ABX NLY MRO 成事影响: AMAG/ATRS 发表发出产Makena己触动打针剂用于投降低早产几比值得到FDA经度过认证，同时发表发出产将在本季度提提交Bremelanotide的报户口新药央寻求 $(AGRX)$周三大跌 47% （盘前一度跌去 74% ），因为其激素避孕贴片Twirla在3期安全研究中表现不如人意（并不是完全失败），公司仍然计划在今年上半年向FDA提出上市申请。 $(CTIC)$周四上涨 12% ，因为FDA宣布其治疗血癌的在研药Pacritinib可以恢复试验。 TEVA暴跌很夸张，如果手里还有股票，不用割了，会有反弹。此股目前价位（23左 右）买入，SWING机会。Generic drug板块（TEVA, MYL等）普遍表现欠佳，受医 疗政策影响大，不做长线。 另外，两个股SWING机会： SNAP触底反弹，13以下买入。长线不看好，参考TWTR表现。